Using SARS-CoV-2 red cell kodecytes to assess vaccine-induced immune response to the conserved 1147-58 region of the spike protein in Indian blood donors: exploring the potential role of blood transfusion services in population surveillance.
Suvro Sankha Datta, Aniruddha Hazra, Najla Haneefa Basheela, Kaushik Gupta, Pradip Kumar Mondal, Elena Aliper, Nicolai V Bovin, Stephen M Henry
{"title":"Using SARS-CoV-2 red cell kodecytes to assess vaccine-induced immune response to the conserved 1147-58 region of the spike protein in Indian blood donors: exploring the potential role of blood transfusion services in population surveillance.","authors":"Suvro Sankha Datta, Aniruddha Hazra, Najla Haneefa Basheela, Kaushik Gupta, Pradip Kumar Mondal, Elena Aliper, Nicolai V Bovin, Stephen M Henry","doi":"10.1016/j.tracli.2025.05.001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Blood transfusion services are uniquely poised to take part in the population surveillance study by providing snapshots of the SARS-CoV-2 immunity status among vaccinated blood donors. The immunogenic 1147-58 region of the intact SARS-CoV-2 spike protein is partly spatially hidden. These 1147-58-region-specific antibodies have previously been observed in COVID-19 infected patients but have not been documented in vaccinated individuals. In this study, we aimed to determine the immune response to this conserved region of the spike protein using SARS-CoV-2 red cell kodecytes among vaccinated blood donors.</p><p><strong>Material and methods: </strong>Three hundred fifteen voluntary blood donors of Indian ethnicity vaccinated twice against SARS-CoV-2 who, to their knowledge, had not had COVID-19 infection, were screened using quantitative chemiluminescent (CLIA) SARS-CoV-2 immunoassay (detecting total S1 IgG antibodies by measuring the binding antibody units [BAU]), as well as a SARS-CoV-2 red cell kodecytes assay detecting IgG antibodies specific to the 1147-58 region by column agglutination technique.</p><p><strong>Results: </strong>The CLIA assay was antibody-reactive with 100% of the 315 samples from vaccinated individuals (BAU/mL > 20), of which 311 (98.7%) were considered immune (BAU/mL > 58). Of the 315 CLIA-reactive samples, moderate to strong kodecyte serologic grades were observed for 63.2% (n = 199) of the samples, while 24.8% (n = 78) yielded weak serologic responses, and 12.1% (n = 38) were unreactive against kodecytes.</p><p><strong>Conclusions: </strong>These results show that about 12% of vaccinated individuals do not have detectable antibodies to the conserved 1147-58 region of the SARS-CoV-2 spike protein and suggest that future studies should clarify whether this has biological implications regarding long-term immune protection.</p>","PeriodicalId":94255,"journal":{"name":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.tracli.2025.05.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Blood transfusion services are uniquely poised to take part in the population surveillance study by providing snapshots of the SARS-CoV-2 immunity status among vaccinated blood donors. The immunogenic 1147-58 region of the intact SARS-CoV-2 spike protein is partly spatially hidden. These 1147-58-region-specific antibodies have previously been observed in COVID-19 infected patients but have not been documented in vaccinated individuals. In this study, we aimed to determine the immune response to this conserved region of the spike protein using SARS-CoV-2 red cell kodecytes among vaccinated blood donors.
Material and methods: Three hundred fifteen voluntary blood donors of Indian ethnicity vaccinated twice against SARS-CoV-2 who, to their knowledge, had not had COVID-19 infection, were screened using quantitative chemiluminescent (CLIA) SARS-CoV-2 immunoassay (detecting total S1 IgG antibodies by measuring the binding antibody units [BAU]), as well as a SARS-CoV-2 red cell kodecytes assay detecting IgG antibodies specific to the 1147-58 region by column agglutination technique.
Results: The CLIA assay was antibody-reactive with 100% of the 315 samples from vaccinated individuals (BAU/mL > 20), of which 311 (98.7%) were considered immune (BAU/mL > 58). Of the 315 CLIA-reactive samples, moderate to strong kodecyte serologic grades were observed for 63.2% (n = 199) of the samples, while 24.8% (n = 78) yielded weak serologic responses, and 12.1% (n = 38) were unreactive against kodecytes.
Conclusions: These results show that about 12% of vaccinated individuals do not have detectable antibodies to the conserved 1147-58 region of the SARS-CoV-2 spike protein and suggest that future studies should clarify whether this has biological implications regarding long-term immune protection.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
